Two drugs are better than one to start T2DM therapy
- PMID: 31705131
- DOI: 10.1038/s41574-019-0294-3
Two drugs are better than one to start T2DM therapy
Comment on
-
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18. Lancet. 2019. PMID: 31542292 Clinical Trial.
References
-
- [No authors listed.] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).
-
- Holman, R. R. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008). - DOI
-
- Laiteerapong, N. et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care 42, 416–426 (2019). - DOI
-
- Brown, J. B., Conner, C. & Nichols, G. A. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 33, 501–506 (2010). - DOI
-
- Phung, O. J. et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes. Metab. 16, 410–417 (2014). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
